Señales en vivo de INDEX.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:29):

Stats
Volumen de hoy	4.43M
Volumen promedio	2.23M
Capitalización de mercado	196.03M
EPS	SEK0 ( 2024-02-20 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-21
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.04
ATR14	SEK0.00200 (0.54%)

Volumen Correlación

Largo: -0.22 (neutral)

Corto: 0.70 (moderate)

Signal:(52.587) Neutral

InDex Pharmaceuticals Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

InDex Pharmaceuticals Correlación - Moneda/Commodity

0.11
( neutral )

0.25
( neutral )

0.00
( neutral )

-0.20
( neutral )

InDex Pharmaceuticals Finanzas

Annual	2023
Ingresos:	SEK97.51M
Beneficio Bruto:	SEK-95.71M (-98.16 %)
EPS:	SEK-0.180

FY	2023
Ingresos:	SEK97.51M
Beneficio Bruto:	SEK-95.71M (-98.16 %)
EPS:	SEK-0.180

FY	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
Ingresos:	SEK1.15M
Beneficio Bruto:	SEK-9.14M (-797.64 %)
EPS:	SEK-0.180

Financial Reports:

No articles found.

InDex Pharmaceuticals

InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.